TrialThe New England journal of medicine2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz et al.PubMed ↗Publisher ↗
The primary results report of NCT01663402. Its numbers are set against the trial’s posted results below.
No numbers read from the abstract.
Against the trial’s posted results
- Same as the trial’s posted resultThis paper HR 0.85 (0.78–0.93)Posted, primary outcome HR 0.85 (0.78–0.93), p = 0.0003Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study
1,449 papers cite itlatest 60 shown
this paperpooled ittrialcites it